Sugi Predict

Sugi Predict / Compounds / SCHEMBL4123685

SCHEMBL4123685

SCHEMBL4123685

CC(C)(C)[Si](OCCC=O)(c1ccccc1)c1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
▸ SMYD2 Q9NRG4 3/20 0.40
▸ CYP3A4 P08684 1/20 0.40
▸ HTT P42858 1/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ ADH1B P00325 1/20 0.35
▸ ADH1C P00326 1/20 0.35
▸ ADH1A P07327 1/20 0.35
▸ ADH7 P40394 1/20 0.35
▸ AOX1 Q06278 1/20 0.33
▸ PPARA Q07869 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10150560 0.91 SMYD2 (0.37) SMYD2CYP3A4HTTSMN1; SMN2ADH1B
SCHEMBL641418 0.90 SMYD2 (0.38) SMYD2CYP3A4HTTSMN1; SMN2ADH1B
SCHEMBL38662 0.89 SMYD2 (0.38) SMYD2CYP3A4HTTSMN1; SMN2ADH1B
SCHEMBL30875949 0.88 SMYD2 (0.36) SMYD2CYP3A4HTTSMN1; SMN2ADH1B
SCHEMBL22664469 0.88 SMYD2 (0.37) SMYD2CYP3A4HTTSMN1; SMN2ADH1B
SCHEMBL20500252 0.88 SMYD2 (0.37) SMYD2CYP3A4HTTSMN1; SMN2ADH1B
SCHEMBL4824010 0.88 SMYD2 (0.37) SMYD2CYP3A4HTTSMN1; SMN2ADH1B
SCHEMBL20500283 0.88 SMYD2 (0.37) SMYD2CYP3A4HTTSMN1; SMN2ADH1B
SCHEMBL20500262 0.88 SMYD2 (0.37) SMYD2CYP3A4HTTSMN1; SMN2ADH1B
SCHEMBL4821411 0.88 SMYD2 (0.37) SMYD2CYP3A4HTTSMN1; SMN2ADH1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250296946-A1 NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF Atrium Therapeutics, Inc. 2025-09-25 — — US disclosed
US-12365704-B2 Nucleic acid-polypeptide compositions and uses thereof AVIDITY BIOSCIENCES, INC. (US) 2025-07-22 — — US disclosed
US-12071436-B2 Anti-parasitic compounds and uses thereof UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (US) 2024-08-27 — — US disclosed
CN-115260165-B Benzo nitrogen-containing five-membered heterocyclic compound and synthesis and application thereof 中国科学院上海药物研究所 2024-08-06 — — CN disclosed
US-20230234978-A1 NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF Atrium Therapeutics, Inc. 2023-07-27 — — US disclosed
US-11578090-B2 Nucleic acid-polypeptide compositions and uses thereof AVIDITY BIOSCIENCES, INC. (US) 2023-02-14 — — US disclosed
CN-115260165-A Benzo nitrogen-containing five-membered heterocyclic compound and synthesis and application thereof 中国科学院上海药物研究所 2022-11-01 — — CN disclosed
US-20220340557-A1 ANTI-PARASITIC COMPOUNDS AND USES THEREOF MEMORIAL SLOAN-KETTERING CANCER CENTER (US) 2022-10-27 — — US disclosed
CN-114375296-A Nucleic acid polypeptide compositions and uses thereof 艾维迪提生物科学公司 2022-04-19 — — CN disclosed
EP-3980436-A1 NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF Avidity Biosciences, Inc. (US) 2022-04-13 — — EP disclosed
EP-1112275-A1 NOVEL HETEROAROMATIC INHIBITORS OF FRUCTOSE 1,6-BISPHOSPHATASE Metabasis Therapeutics, Inc. (US) 2001-07-04 — — EP disclosed
WO-2000038666-A2 A COMBINATION OF FBPase INHIBITORS AND INSULIN SENSITIZERS FOR THE TREATMENT OF DIABETES METABASIS THERAPEUTICS, INC. (US) 2000-07-06 — — WO disclosed
WO-2000014095-A1 NOVEL HETEROAROMATIC INHIBITORS OF FRUCTOSE 1,6-BISPHOSPHATASE METABASIS THERAPEUTICS, INC. (US) 2000-03-16 — — WO disclosed
US-5877199-A ALZHEIMER'S DISEASE; SEDATIVE SANKYO COMPANY, LIMITED (JP) 1999-03-02 — — US disclosed
EP-0804416-A1 HETEROCYCLIC COMPOUNDS, USEFUL AS ALLOSTERIC EFFECTORS AT MUSCARINIC RECEPTORS SANKYO COMPANY LIMITED (JP) 1997-11-05 — — EP disclosed
WO-1996003377-A1 HETEROCYCLIC COMPOUNDS, USEFUL AS ALLOSTERIC EFFECTORS AT MUSCARINIC RECEPTORS SANKYO COMPANY, LIMITED (JP) 1996-02-08 — — WO disclosed
EP-0532423-A1 Novel unsaturated acyclic phosphonate derivatives of purine and pyrimidine MERRELL DOW PHARMACEUTICALS INC. (US) 1993-03-17 — — EP disclosed
US-5120729-A Enzyme inhibitors MERCK & CO., INC. (US) 1992-06-09 — — US disclosed
EP-0462667-A2 Beta-lactams as antihypercholesterolemics MERCK & CO. INC. (US) 1991-12-27 — — EP disclosed
EP-0353732-A2 Fluoro-olefins, method for their preparation and their use CIBA-GEIGY AG (CH) 1990-02-07 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12365704-B2 Nucleic acid-polypeptide compositions and uses thereof POLM, POLN, POLI SMYD2 3428/4885CYP3A4 4860/4885HTT 1038/4885
US-12071436-B2 Anti-parasitic compounds and uses thereof MPO, GOT2, GOT1 SMYD2 3628/4885CYP3A4 862/4885HTT 2881/4885
US-11578090-B2 Nucleic acid-polypeptide compositions and uses thereof POLM, POLN, POLI SMYD2 3428/4885CYP3A4 4860/4885HTT 1038/4885
US-20220340557-A1 ANTI-PARASITIC COMPOUNDS AND USES THEREOF MPO, GOT2, GOT1 SMYD2 3628/4885CYP3A4 862/4885HTT 2881/4885
US-20230234978-A1 NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF POLM, POLN, POLI SMYD2 3428/4885CYP3A4 4860/4885HTT 1038/4885
US-20250296946-A1 NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF POLM, POLN, POLI SMYD2 3428/4885CYP3A4 4860/4885HTT 1038/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.